TATVANSETatva Chintan Pharma Chem Limited· Chemicals & PetrochemicalsHighNeutral
Announced Wed, 21 Jan, 2026 · 15:52 IST

Tatva Chintan Q3 FY26: Revenue up about 53%, PAT jumps to Rs 151.65 million

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing

TATVA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-8.8%Reaction day
₹1395.00
prior close
₹1434.20
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.6%-10.4% vs market
Specialty Chemicals peers, median of 85sector+1.1%-9.9% vs sector

On the reaction day the stock moved 10.4 pts less than Nifty Microcap 250 and 9.9 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.0
10m
-1.0
15m
-2.0
30m
-4.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-8.8+1.6-10.4+1.1-9.9
Next day
-17.7-0.6-17.1-0.2-17.5
2d
-19.2-0.5-18.7-1.1-18.1
3d
-16.3+1.5-17.9+0.6-17.0
4d
-19.7+1.1-20.9+0.4-20.1
5d
-17.0+3.0-20.0+1.2-18.2
1w
-10.1+5.5-15.5+2.7-12.8
15d
-14.6+6.1-20.7+3.0-17.6
1m
-12.3+5.1-17.4+1.2-13.4
2m
-19.5-8.0-11.5-11.0-8.5
3m
-4.7+10.9-15.6+5.4-10.1
UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 85Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone and consolidated unaudited results for Q3 and 9M FY26 ended Dec 31, 2025. Consolidated revenue rose about 53 percent YoY to Rs 1,313.34 million. PAT jumped to Rs 151.65 million from Rs 1.38 million. For 9M FY26, consolidated revenue grew around 35 percent to Rs 3,717.04 million and PAT climbed to Rs 317.33 million from Rs 46.83 million. Standalone PAT swung to Rs 159.84 million from a loss. Auditor NDJ and Co. gave an unmodified review.

Likely market impact

Strong rebound as revenue and profit surge sharply YoY. Likely positive for investor sentiment.